Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance-Reference-Cited by-同舟云学术

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

Published:2018-05-10 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Pettitt Stephen J.^ORCID,Krastev Dragomir B.,Brandsma Inger,Dréan Amy,Song Feifei,Aleksandrov Radoslav,Harrell Maria I.,Menon Malini,Brough Rachel,Campbell James,Frankum Jessica,Ranes Michael,Pemberton Helen N.,Rafiq Rumana,Fenwick Kerry,Swain Amanda,Guettler Sebastian^ORCID,Lee Jung-Min,Swisher Elizabeth M.,Stoynov Stoyno,Yusa Kosuke,Ashworth Alan,Lord Christopher J.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-03917-2.pdf

Reference56 articles.

1. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).

2. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).

3. Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152–1158 (2017).

4. Mortusewicz, O., Amé, J.-C., Schreiber, V. & Leonhardt, H. Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res. 35, 7665–7675 (2007).

5. Murai, J. et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 13, 433–443 (2014).

Cited by 339 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes;Expert Review of Anticancer Therapy;2024-09-03

2. PARPi, BRCA, and gaps: controversies and future research;Trends in Cancer;2024-09

3. Regulation of PARP1/2 and the tankyrases: emerging parallels;Biochemical Journal;2024-08-23

4. Strategies for the prevention or reversal of PARP inhibitor resistance;Expert Review of Anticancer Therapy;2024-08-20

5. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance;Molecular Cancer;2024-08-05